Profile data is unavailable for this security.
About the company
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
- Revenue in USD (TTM)0.00
- Net income in USD-18.65m
- Incorporated2016
- Employees40.00
- LocationAptevo Therapeutics Inc2401 4th Ave Ste 1050SEATTLE 98121-3460United StatesUSA
- Phone+1 (206) 838-0500
- Fax+1 (206) 838-0503
- Websitehttp://aptevotherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AgriFORCE Growing Systems Ltd | 16.28k | -11.73m | 3.34m | 7.00 | -- | 0.101 | -- | 205.36 | -14.14 | -14.14 | 0.014 | 1.47 | 0.0008 | -- | 0.408 | 2,325.71 | -59.84 | -78.95 | -84.37 | -109.86 | 16.58 | -- | -72,071.25 | -243,182.50 | 0.6922 | -1.39 | 0.3253 | -- | -- | -- | 8.85 | -- | 48.61 | -- |
| Marizyme Inc | 590.91k | -79.15m | 3.36m | 13.00 | -- | -- | -- | 5.69 | -1.83 | -1.83 | 0.0139 | -0.4704 | 0.0117 | 0.9575 | 12.13 | 45,454.62 | -157.28 | -29.47 | -314.26 | -30.42 | 71.63 | 67.78 | -13,393.85 | -8,518.47 | 0.025 | -0.5887 | -- | -- | 11.04 | 18.20 | -247.03 | -- | -- | -- |
| NovaBay Pharmaceuticals Inc | 14.73m | -16.70m | 3.42m | 24.00 | -- | 0.7813 | -- | 0.2324 | -3.82 | -3.82 | 3.50 | 0.2951 | 1.16 | 2.16 | 10.78 | 613,583.30 | -75.81 | -61.51 | -114.10 | -83.89 | 53.61 | 59.99 | -65.46 | -86.47 | 0.9998 | -- | 0.2555 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
| Aptevo Therapeutics Inc | 0.00 | -18.65m | 3.55m | 40.00 | -- | 0.0358 | -- | -- | -77.09 | -70.57 | 0.00 | 27.62 | 0.00 | -- | -- | 0.00 | -63.16 | -47.16 | -86.49 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
| Atreca Inc | 0.00 | -97.76m | 3.58m | 90.00 | -- | 0.3322 | -- | -- | -2.49 | -2.49 | 0.00 | 0.2715 | 0.00 | -- | -- | 0.00 | -98.54 | -44.99 | -116.19 | -48.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.13 | -- | -8.46 | -- |
| Yield10 Bioscience Inc | 60.00k | -14.46m | 3.60m | 29.00 | -- | -- | -- | 59.97 | -50.04 | -50.04 | 0.1815 | -4.95 | 0.01 | -- | 4.00 | 2,068.97 | -241.08 | -91.26 | -524.02 | -108.09 | -- | -- | -24,091.67 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
| Biostax Corp | 0.00 | -1.65m | 3.60m | -- | -- | -- | -- | -- | -0.0198 | -0.0198 | 0.00 | -0.0456 | 0.00 | -- | -- | -- | -193.36 | -75.14 | -- | -- | -- | -- | -- | -- | -- | -8.97 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -10.06m | 3.61m | 21.00 | -- | 0.5998 | -- | -- | -1.93 | -1.93 | 0.00 | 0.5447 | 0.00 | -- | -- | 0.00 | -125.53 | -132.00 | -149.91 | -157.28 | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| Optimus Healthcare Services Inc | 1.27m | -7.79m | 3.63m | 17.00 | -- | -- | -- | 2.87 | -0.1948 | -0.1948 | 0.0317 | -0.1291 | 0.2595 | -- | 2.16 | 74,453.53 | -159.79 | -- | -2,228.37 | -- | 77.90 | -- | -615.77 | -- | 0.1525 | -15.41 | 21.18 | -- | -- | -- | -- | -- | -- | -- |
| Altamira Therapeutics Ltd | 0.00 | -8.03m | 3.67m | 10.00 | -- | 0.3397 | -- | -- | -16.35 | -8.70 | 0.00 | 4.83 | 0.00 | 34.05 | 32.30 | 0.00 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -- | -- | 1.38 | -4.37 | 0.00 | -- | -- | -- | 61.02 | -- | -- | -- |
| Finch Therapeutics Group Inc | 107.00k | -74.75m | 3.69m | 18.00 | -- | 0.1614 | -- | 34.52 | -46.59 | -46.59 | 0.0667 | 14.25 | 0.001 | -- | 1.49 | -- | -68.48 | -- | -74.93 | -- | -- | -- | -69,863.55 | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| Geovax Labs Inc | 0.00 | -25.97m | 3.72m | 17.00 | -- | 0.5523 | -- | -- | -14.25 | -14.25 | 0.00 | 2.91 | 0.00 | -- | -- | 0.00 | -127.82 | -108.34 | -160.47 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Livewire Ergogenics Inc | 67.98k | -1.09m | 3.72m | 1.00 | -- | -- | -- | 54.72 | -0.0061 | -0.0061 | 0.0003 | -0.0022 | 0.1979 | 1.74 | 2.86 | 67,980.00 | -317.45 | -- | -- | -- | -113.70 | -- | -1,604.38 | -- | 0.1248 | -2.13 | -- | -- | 68.58 | -- | -3.64 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -10.83m | 3.76m | 8.00 | -- | 0.3974 | -- | -- | -6.40 | -6.40 | 0.00 | 2.06 | 0.00 | -- | -- | 0.00 | -97.63 | -71.92 | -116.38 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Clearmind Medicine Inc | 0.00 | -8.09m | 3.77m | -- | -- | 0.7482 | -- | -- | -30.92 | -30.92 | 0.00 | 1.59 | 0.00 | -- | -- | -- | -109.55 | -218.20 | -180.61 | -488.96 | -- | -- | -- | -- | -- | -2.90 | 0.0184 | -- | -- | -- | -25.03 | -- | -- | -- |
Data as of May 06 2024. Currency figures normalised to Aptevo Therapeutics Inc's reporting currency: US Dollar USD
6.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2023 | 11.75k | 1.74% |
| Sabby Management LLCas of 31 Dec 2023 | 7.94k | 1.18% |
| Citadel Securities LLCas of 31 Dec 2023 | 5.96k | 0.89% |
| Schonfeld Strategic Advisors LLCas of 31 Dec 2023 | 3.61k | 0.54% |
| Squarepoint OPS LLCas of 31 Dec 2023 | 3.15k | 0.47% |
| Millennium Management LLCas of 31 Dec 2023 | 2.38k | 0.35% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.09k | 0.31% |
| Armistice Capital LLCas of 31 Dec 2023 | 1.39k | 0.21% |
| Cantor Fitzgerald Europeas of 31 Dec 2023 | 1.33k | 0.20% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.06k | 0.16% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
